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Abstract: Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since 
the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated 
protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when 
needed to diagnose, monitor and/or treat PCa patients successfully. One enhancement could include 
the simultaneous detection of multiple PCa-associated protein biomarkers alongside PSA, also 
known as multiplexing. If conventional methods such as the enzyme-linked immunosorbent assay 
(ELISA) are used, multiplexed detection of such protein biomarkers can result in an increase in the 
required sample volume, in the complexity of the analytical procedures, and in adding to the cost. 
Using companion diagnostic devices such as biosensors, which can be portable and cost-effective 
with multiplexing capacities, may address these limitations. This review explores recent research 
for multiplexed PCa protein biomarker detection using optical and electrochemical biosensor plat-
forms. Some of the novel and potential serum-based PCa protein biomarkers will be discussed in 
this review. In addition, this review discusses the importance of converting research protocols into 
multiplex point-of-care testing (xPOCT) devices to be used in near-patient settings, providing a 
more personalized approach to PCa patients’ diagnostic, surveillance and treatment management. 
Keywords: prostate cancer; multiplex point-of-care testing (xPOCT); protein biomarkers; compan-
ion diagnostic devices 
 
1. Introduction 
Prostate cancer (PCa) is one of the most prevalent cancer types for men worldwide 
[1]. So far, prostate-specific antigen (PSA) has been considered to be an important bi-
omarker for PCa diagnostic testing. In 1994, the use of a PSA screening test in combination 
with a digital rectal examination (DRE) was approved by the U.S. Food and Drug Admin-
istration (FDA) [2]. The PSA screening test is a standard clinical diagnostic test, comprised 
of a blood analysis for the quantification of PSA. According to established guidelines, se-
rum PSA levels above 4 ng/mL provide an indication that PCa is present in an individual. 
However, PSA levels, particularly those between 4 and 10 ng/mL, are referred to as the 
diagnostic gray zone, in which elevated serum levels can be associated with other benign 
conditions, which can often be age-specific, such as benign prostatic hyperplasia (BPH) or 
prostatitis [3]. In addition to this, “normal” or “healthy” serum PSA levels (<4 ng/mL) can 
also be found in PCa patients. Therefore, the PSA test is lacking in both sensitivity and spec-
ificity for early detection of PCa. Leading to tentative misdiagnosis or needless and invasive 
prostate biopsies or radical prostatectomies for numerous PCa patients [4,5]. Other PSA de-
rivatives have been calculated to improve PSA specificity, such as age-specific PSA cut-offs, 
percentages between free PSA and total PSA (%fPSA), PSA density (PSAD) and PSA veloc-
ity (PSAV) [5–10]. However, these attempts have not greatly increased the sensitivity and 
the specificity of the PCa diagnosis and treatment management. On the other hand, DRE 
testing normally has good specificity, e.g., DRE has been able to determine approximately 
25% of clinically significant PCa patients who had been originally reported to display 
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“normal” PSA serum levels [11,12]. However, this examination has a major drawback of 
variability depending on the experience of the examiner [12–14]. 
Because of the variations in the sensitivity and specificity of PSA and/or DRE tests, 
one significant research approach has been to simultaneously detect a panel of PCa pro-
tein biomarkers, also known as multiplexing [15–21]. Biomarkers for PCa can be identified 
in a variety of bodily samples, including prostatic tissue, serum and urine. Other bi-
omarkers that could be examined include DNA methylation, microRNAs, circulating tu-
mor DNA (ctDNA), metabolomics, volatile organic compounds (VOCs), and circulating 
tumor cells (CTCs) [10,22–25]. However, because of the widespread clinical and commer-
cial ease of quantifying serum protein levels, especially when using traditional biomarker 
detection methods, this review concentrates on serum PCa protein biomarkers [10]. Po-
tential PCa-associated protein biomarkers that have been identified (including those that 
have not been validated to date) for diagnostic, prognosis, and predictive stages, will be 
discussed in this review. 
Conventional biomarker detection methods are used in clinical laboratory environ-
ments such as surface plasmon resonance, fluorescence analysis and enzyme-linked im-
munosorbent assay (ELISA) [26]. Of which ELISA is a typical gold-standard technique 
used for single-analyte detection of protein biomarkers retrieved from patient’s samples 
such as serum or urine [27]. However, conventional ELISA analysis is a lengthy and labo-
rious process, requiring highly qualified professionals [28]. Furthermore, it is not a suita-
ble method for a more reliable and tailored approach to PCa care and treatment manage-
ment when trying to achieve precise, accurate outcomes while using a minute sample vol-
ume to detect several protein biomarkers [16,26,29]. 
Several biosensor platforms integrated with microfluidic systems have demonstrated 
multiple benefits when compared to ELISA, so that results can be obtained easily, requir-
ing less steps and reducing costs [30]. This review aims to give an overview of the recent 
advances in biosensor systems that simultaneously detect multiple PCa-related proteins 
using optical or electrochemical detection techniques; it offers an insight into possible and 
effective integrated systems that can be translated into multiplex point-of-care testing 
(xPOCT) devices to be used in near-patient environments, such as hospitals, GP clinics or 
within patient’s homes. 
2. Potential PCa Protein Biomarkers 
Although PSA (human kallikrein 3, hK3) is a serine protease produced by epithelial 
cells inside the prostate gland, it is not specific to PCa [10,19,31,32]. Elevated levels of 
serum PSA may be caused by other factors than adenocarcinoma of the prostate. In addi-
tion, PCa can be present in men with low serum PSA levels (<4 ng/mL). However, as men-
tioned previously, PSA derivatives have been found to be of some clinical use to increase 
the sensitivity and specificity of PCa diagnosis [32,33]. 
Generally, multiple molecular isoforms of PSA circulate in serum [32,34]. For in-
stance, approximately 70% of PSA can be found in serum as complexed PSA (cPSA), in 
which PSA is bound to serine protease inhibitors, such as α1-antichymotrypsin (ACT) and 
α2-macroglobulin [35,36]. About 30% of PSA do not form complexes with serine protease 
inhibitors, and are known as free PSA (fPSA), which in itself has several variants such as 
proenzyme PSA (proPSA) and intact or inactive PSA (iPSA) [36,37]. fPSA has been shown 
to be under-expressed in PCa patients relative to healthy patients or patients found to 
have benign diseases. Low fPSA serum levels have also been correlated with aggressive 
PCa [38]. Combinations of both cPSA and fPSA, with other PSA molecular isoforms is 
known as total PSA (tPSA) or simply PSA. tPSA and fPSA have been analyzed in combi-
nation, to calculate the %fPSA of patients with tPSA serum levels within the diagnostic 
gray zone (between 4 and 10 ng/mL). It has been shown that a higher %fPSA suggests 
lower probability of PCa on biopsy and raises the likelihood of an increase in PSA caused 
by BHP. However, both the %fPSA and PSA screening tests are constrained in their ana-
lytical performance to provide consistent diagnosis of PCa due to inter-assay variability 
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[32,39]. In addition, more research into detecting multiple PSA isoforms using serum-
based immunoassays has led to the development and commercialization of the Prostate 
Health Index (PHI; Beckman Coulter) and the 4-kallikrein score test (4Kscore® Test; OPKO 
Health), both of which are used in clinical laboratories to help with the decision of whether 
an initial or repeat biopsy should be performed [5]. 
The Prostate Health Index (PHI) was approved by the FDA in 2012 for PCa diagnosis 
and active surveillance of PCa patients. The PHI compares serum protein levels of fPSA, 
tPSA, and a variant of pPSA called [−2]proPSA (or p2PSA) using the equation 
(p2PSA/fPSA) × tPSA1/2) [5,10,37,40]. The PHI test is intended for males over the age of 50 
who have PSA values of less than 10 ng/mL, a normal DRE examination and are planning 
or reconsidering a prostate biopsy [41]. The PHI has been proven to have a diagnosis ac-
curacy of 71% and a specificity of 26%, avoiding up to 40% of needless biopsies. Despite 
the fact that it has been demonstrated to outperform just evaluating fPSA or tPSA serum 
levels [5,10,37], the question of setting the cut off threshold for clinically significant PCa 
patients remains unanswered [40]. Furthermore, the 4-kallikrein score test (4Kscore® Test) 
is a prediction model that uses laboratory analysis along with clinical characteristics such 
as age, prior prostate biopsy, and DRE results to provide the best prognosis for PCa pa-
tients [5,10,37,40]. The laboratory test comprises the measurement of four kallikrein pro-
teins, including three PSA isoforms: fPSA, tPSA, and iPSA, as well as human kallikrein 2 
(hK2), which is 80 percent homologous to PSA [10,37]. Overall, this test is for men who 
have high PSA levels and a positive DRE examination result. It has been found in multiple 
validation studies to eliminate needless biopsies while also being able to identify men 
with clinically severe PCa. However, there are certain restrictions on when this test can be 
performed. For example, it can only be conducted if men have not had a DRE in the last 
96 h, or if they have not had any therapy or procedure for BHP symptoms [42]. Despite 
the fact that these tests have been thoroughly confirmed, research suggests that one 
method to improve their specificity is to select meaningful protein biomarkers other than 
PSA and related isoforms [10]. 
Currently, many emerging and potential PCa protein biomarkers have been identi-
fied (see Table 1), in particular relating to the diagnostic, prognostic or predictive stages 
of a PCa patient [16]. As illustrated in Figure 1, the function of a biomarker is to act as a 
biological indicator to determine any biological change that is contrary to normal biolog-
ical conditions [10,43,44]. The main feature that needs to be taken into consideration are 
whether the biomarker has the ability to differentiate PCa from other benign prostatic 
conditions (diagnostic biomarker). In addition, PCa biomarkers should be able to provide 
a forecast discriminating insignificant or indolent PCa from clinically significant or ag-
gressive PCa (prognostic biomarker). Furthermore, PCa protein biomarkers should be able 
to give insight of the likely patient response through active surveillance or during treatment 
(e.g., hormone therapy or chemotherapy), in order to proceed with the ideal treatment path-
way (predictive biomarker) [10]. Unfortunately, it is very unlikely that a single biomarker 
will show all of these desirable characteristics, particularly because the majority of the bi-
omarkers referred to in Table 1 of this review and in other respective reviews are not PCa-
specific since they are associated with several other cancers or diseases. At the same time, 
however, simultaneously detecting multiple biomarkers instead of using single-analyte 
quantification methods may provide more accurate analysis within the diagnostic, prog-
nostic and predictive stages of PCa [30,43,45]. Further developments are required to accu-
rately determine the significance of each protein biomarker to be called a PCa-associated 
biomarker in order to efficiently predict PCa-related results, tailored for each PCa patient 
[43]. 




Figure 1. Desirable characteristics of ideal PCa-associated biomarkers. Reproduced with permission 
from ref [43]. Copyright 2010 Ivyspring InternationalPublisher. 
Table 1. Selected candidate serum protein biomarkers with the potential of being detected within the diagnostic, prognos-
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3. Multiplexed Detection of PCa Protein Biomarkers via Miniaturized Biosensor Systems 
As previously stated, there has been a lot of focus on developing biosensors that de-
tect numerous PCa protein biomarkers simultaneously, a process known as multiplexing, 
in order to improve decision-making during the critical PCa milestones (diagnostic, prog-
nostic, and predictive stages). Antibodies are the most extensively used bioreceptor for 
detecting these protein biomarkers. When antibodies bind to their target antigen, whether 
via a sandwich or competitive assay, the overall set-up is referred to as an immunoassay 
[84]. Immunosensors involve the use of a biosensor platform in order to monitor the im-
munoassay from which binding events between antibodies and their respective PCa bi-
omarker can be evaluated using several transducers such as mass-sensitive, electrochem-
ical or optical transducers [84]. The focus of this section is to highlight current research 
achievements, demonstrating the sensitive simultaneous detection of multiple serum PCa 
protein biomarkers using optical and electrochemical transducers. Several optical detec-
tion protocols have been devised to quantify certain target analytes, including lumines-
cence [85], surface-enhanced Raman scattering [86], and surface plasma resonance [87] 
detection techniques. Additionally, research has been performed on the application of am-
perometric, voltammetric and impedimetric methods for multiplex electrochemical bio-
sensor detection. The advantages and disadvantages of using both optical and electro-
chemical techniques are further assessed in more detail by Roda et al. [88]. 
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Figure 2 describes various approaches to multiplexing, which include: the use of spa-
tially separated detection sites for each biomarker; spatially divided regions within a 
channel network or electrode array; the use of several labels such as enzymes, metallic 
nanoparticles, or magnetic microbeads; and finally the use of spatially encoding on a sin-
gle transducer surface using multiple labels (also known as barcoding) [16,20,89]. Some of 
these multiplexing approaches have been shown to improve the sensitivity of the biosen-
sor during PCa protein detection and also have the potential to become commercially 
available xPOCT devices for PCa treatment management. For example, some of the re-
search discussed includes the use of low-cost technologies to produce proof-of-concept 
prototypes or the integration of microfluidic systems to provide automated operation of 
biosensor platforms while requiring lower sample volumes [90,91]. 
 
Figure 2. Schematic to multiplexing approaches in order to simultaneously detect multiple target 
analytes of interest. 
3.1. Optical Detection Methods 
3.1.1. Luminescence 
Luminescence generates a variety of cold light emissions, as it is not governed by the 
rising temperatures, as seen with incandescent detection platforms [92]. Thus, this type of 
optical detection technique generally involves an excited molecule that emits light energy 
while returning to its electronic ground state [93]. In terms of multiplexed detection of 
PCa protein biomarkers, the fluorescent, chemiluminescent and electro-chemiluminescent 
methods will be discussed below. 
Fluorescence 
Fluorescence is a type of photoluminescence that is initiated by the absorption of light 
energy (photons). This physical phenomenon is also known as photoexcitation [93]. Pho-
todetectors are used to measure the changes in intensity after binding events of the target 
analyte and bioreceptor [94]. The labels only emit light at certain wavelengths when the 
analyte is found [30]. 
Rong et al. developed a fluorescent lateral flow immunoassay (LFIA) using dual-
color magnetic-quantum dot nanobeads (MQBs) to detect fPSA and cPSA simultaneously, 
as shown in Figure 3 [95]. Initially, protein biomarkers were attached to the capture anti-
bodies modified with red (MQB625) and green (MQB525) colored MQBs, for fPSA and 
cPSA respectively, using an off-line capture protocol. After magnetic separation from un-
bound MQBs, the respective capture antibodies (anti-fPSA and anti-cPSA), were used as 
fluorescent detection probes. Subsequently, the sample solution was introduced to the 
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LFIA, and using capillary forces, the sample solution migrated to the sensor surface im-
mobilized with the monoclonal anti-tPSA detection antibodies to the nitrocellulose mem-
brane, forming a sandwich format. Fluorescent images were analyzed using a dual-color 
strip readout integrated into a smartphone, as UV LED light stimulated the fluorescent 
detection probes attached to the protein biomarkers. The limits of detection for fPSA and 
cPSA in diluted fetal bovine serum were 0.009 and 0.087 ng/mL, respectively, within 1 h. 
Further to this, the LFIA was able to distinguish between clinical samples obtained from 
PCa and BPH patients when simultaneously detecting fPSA and cPSA in order to evaluate 
the %fPSA. Moreover, the clinical sample results were well correlated with the reference 
method, chemiluminescent microparticle immunoassay. It was concluded that the LFIA 
prototype could be specifically used as a xPOCT device in low-resource environments 
providing accurate diagnosis of PCa patients. 
 
Figure 3. Smartphone-based dual-color fluorescent LFIA reader; (A) Internal structure of the smartphone readout device. 
MQB625 and MQB525 conjugates captured on the test line were excited by a 365 nm UV LED light source. Red and green 
emission signals passed through a dual-band emission filter (524/628 nm) and an external plano-convex lens, before reaching 
the smartphone CMOS sensor, (B) Depiction of the smartphone readout device. Reproduced with permission from ref [95]. 
Copyright 2019 Elsevier. 
Chemiluminescence 
Chemiluminescence (CL) is initiated by a chemical reaction between at least two lu-
minescent reagents and is manipulated by the fluid flow [92,94,96]. The energy produced 
by the reaction of chemical reagents together causes the production of light [97]. The most 
common example of chemiluminescent detection involves the chemical interaction be-
tween luminol and horseradish peroxidase (HRP) [98]. 
For instance, Tang et al. have demonstrated the use of this detection technique to 
detect the PCa biomarkers PF-4 and PSA using an automated 3D-printed microfluidic ar-
ray [99]. Using a touchscreen interface to operate the system’s pump, a sandwich format 
was constructed, by first immobilizing spotted arrays of poly L-lysine-coated glass slides 
with capture antibodies that bind to its respective protein biomarkers. This was followed 
by detection antibodies which were attached to several horseradish peroxidase labels (pol-
yHRP) forming Ab2-polyHRP conjugates. The CL reagents were introduced to the detec-
tion chamber after the flow of the wash buffer. From which luminol reacted with hydro-
gen peroxide (H2O2) and was oxidized in the presence of HRP. The signal was measured 
using a coupled charged device (CCD) camera. A detection limit of 0.5 pg/mL was 
achieved for PF-4 and PSA in diluted calf serum within 30 min. The accuracy of the results 
was also confirmed by correlating results with ELISA assays using serum samples from 
non-PCa and PCa patients. Thus, it presents great opportunities to be used as a PCa 
xPOCT diagnostic device in resource-limited environments, because it is not only re-usa-
ble and fast but also cost-effective compared to the traditional ELISA. 
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Jolly et al. demonstrated an aptamer-based ELISA that replaced capture antibodies 
in a sandwich immunoassay with DNA aptamers for the quantification of fPSA and the 
glycoprofiling of fPSA [100]. It has been suggested that glycoprofiling of fPSA could be 
used to distinguish between indolent and aggressive forms of PCa. Thus, reducing unnec-
essary biopsies and further treatments that may have a negative impact on PCa patients 
[101]. A detection antibody, HRP-labeled anti-fPSA, was used for fPSA quantification 
within a single microchannel as shown in Figure 4. Whereas the parallel channel had the 
biotinylated Sambucus nigra (SNA) lectin (a biological protein) with a complementary 
streptavidin-HRP label, forming an aptamer-lectin assay for fPSA glycoprofiling. The op-
tical changes that occurred during the binding of the respective receptors to fPSA were 
measured using a microfluidic CL sensor, via a microscopic CCD camera, after luminol 
had flowed into the respective microchannels. Detection limits for fPSA and fPSA glycans 
were 0.5 and 3 ng/mL in PBS, respectively. The detection limits are both relevant to the 
clinical ranges achieved using standard antibody-based immunoassays to evaluate the di-
agnosis or prognosis PCa patients [100]. 
 
Figure 4. Illustration of microfluidic channel fabrication scheme for the quantification and glyco-
profiling of fPSA. Reproduced with permission from ref [100]. Copyright 2016 Elsevier. 
Zhao et al. used a dual-labeled CL immunoassay to simultaneously measure tPSA 
and fPSA from diluted human serum samples in just over 1 h [102]. A sandwich immu-
noassay was also used, in which capture monoclonal antibodies were first immobilized 
on the sensing platform. However, two different labels, HRP and alkaline phosphatase 
(ALP), were used to differentiate between tPSA and fPSA detection monoclonal antibod-
ies. The HRP-labeled antibody bound to both cPSA and fPSA was used to determine the 
amount of tPSA present in the sample. Whereas only fPSA was recognized by the ALP-
labeled antibody. As a result, two chemiluminescence reactions occurred during the de-
tection measurement as HRP reacted with luminol, ALP reacted with its respective CL 
substrate, 4-methoxy-4-(3-phosphate-phennyl)-spiro-(1,2-dioxetane-3,2′adamantane) 
(AMPPD). Detection limits of 0.03 and 0.05 ng/mL were found for tPSA and fPSA. The 
results obtained from this assay were also correlated with commercial chemiluminescent 
kits using clinical samples. It was concluded that this device would be useful for early 
diagnosis of PCa and could be used for routine clinical testing [102]. 
Electrochemiluminescence 
In contrast to CL, electrochemiluminescence (ECL) is electrochemically generated, and 
therefore electron transfer at or near the working electrode is initiated and manipulated only 
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after the application of the potential [94,96,98,103]. From which the light intensity emitted is 
detected due to the excited state of the reagents during the ECL reaction [92,96,104]. 
Sardesai et al. used the ECL to simultaneously detect PSA and IL-6 using a microwell 
single-wall carbon nanotube (SWCNT) immunoarray [105]. The SWCNT forests were sit-
uated within the hydrophobic polymer walls formed on a pyrolytic graphite (PG) chip 
inked with poly(butadine), in order to provide a conductive environment for ECL meas-
urements. The array also consisted of a sandwich format with capture antibodies and de-
tection antibodies. The detection antibodies were coated with tris(bipyridine)ruthe-
nium(II) chloride ([Ru(bpy)3]2+) doped with silica nanoparticles (Ab2/RuBPY-SiNP). Both 
detection antibodies for PSA and IL-6 were bound to the same RuBPY-SiNPs in this study. 
To measure ECL, an electrolyte solution containing an ECL enhancer, tripropylamine 
(TrpA), initiated a chemical reaction with [Ru(bpy)3]2+ at 0.95 V vs. Ag/AgCl. Once the 
potential was applied, photoexcited [Ru(bpy)3]2+ was produced and was detected for 400 
s using a CCD camera, only when an intensity of light was emitted at 610 nm. Detection 
limits were 1 pg/mL for PSA and 0.25 pg/mL for IL-6 in undiluted calf serum. Results 
using this array with patients’ serum also correlated with the ELISA single-protein analyte 
kits. Following this study, the same group adapted the microwell SWCNT immunoarray 
by integrating it with a microfluidic system for the detection of the same protein bi-
omarkers (PSA and IL-6), which reduced the total assay time to just over an hour in com-
parison to three-hours when using non-microfluidic arrays [106]. The microfluidic system 
consisted of three molded polydimethylsiloxane (PDMS) channels which were situated 
on top of the chip and supported by a poly(methylmethacrylate) (PMMA) plate. The sys-
tem also included a pump, a sample injector and a switching value for directing solutions 
to their respective channels. The authors achieved low detection limits for PSA (100 
fg/mL) and IL-6 (10 fg/mL) in calf serum. The microfluidic device required only 2.5 µL of 
serum samples to preform triplicate analyses. 
Kadimisetty et al. developed a 30-well microfluidic immunoarray using a low-cost 
automated microprocessor to detect four PCa protein biomarkers in less than 40 min [107]. 
The microprocessor was integrated with printed circuit board (PCB)-controlled micro-
pumps, which were connected to six PDMS channels, as shown in Figure 5. SWCNT forests 
were also immobilized on the PG wafer to amplify the conductivity of the surface area. In 
this research protocol, RuBPY-SiNPs were coated with two antibody mixtures to form two 
duplex Ab2/RuBPY-SiNP detection labels, where label 1 was for PSA and IL-6 and label 2 
for PSMA and PF-4. Within 36 min, low detection limits of 50, 100, 10 and 10 fg/mL were 
achieved for PSA, PSMA, PF-4 and IL-6 in undiluted calf serum, respectively. Excellent cor-
relation was achieved with PCa patient serum compared to single-protein ELISA kits. 
Additionally, Kadimisetty et al. designed a 3D-printed supercapacitor-powered im-
munoarray to detect PSA, PSMA and PF-4 [108]. The supercapacitor was used to recharge 
the sensor system using solar cells between ECL measurements. The simplicity of the pro-
tocol reduced the cost of the immunoarrays’ materials, while achieving ultrasensitive detec-
tion within 35 min, which is comparable to their previous work. Detection limits of 300 
fg/mL for PSA, 535 fg/mL for PSMA and 420 fg/mL for PF-4 were achieved in serum. The 
device, as depicted in Figure 6, could be used as a xPOCT in a low-resourced environment. 




Figure 5. A microfluidic immunoarray with a 30-well detection array attached to PCB-controlled mi-
cropumps and sample/reagent cassette. The Arduino microcontroller is the microprocessor used to 
function the micropumps in order to perform the assay. Reproduced with permission from ref [107]. 
Copyright 2015 American Chemical Society. 
 
Figure 6. Illustration of 3D-printed supercapacitor-powered immunoarray using ECL detection 
technique. Reproduced with permission from ref [108]. Copyright 2015 Elsevier. 
Further to this, Kadimisetty et al. developed another cost-effective 3D-printed immu-
noarray to detect eight potential PCa protein biomarkers via ECL. This included a 16 mi-
crowell detection chip, and a microfluidic system integrated with a user-friendly touch 
screen interface, as depicted in Figure 7. The touch screen interface was used to control 
the automated micropump which is connected to the microarray’s inlet port in to order to 
deliver samples and reagents in a timely manner [52]. The authors used the method men-
tioned earlier in the Sardesai et al. study [106], which involved the use of four duplex 
Ab2/RuBPY-SiNP detection labels (label 1 for PSA and PSMA, label 2 for VEGF-D and PF-
4, label 3 for CD-14 and IGF-1, and label 4 for GOLM-1 and IGFBP-3). Once the detection 
antibodies have been attached to their target protein, TprA solution was introduced to the 
detection platform. The light intensity of the ECL reactions was measured using a CCD 
camera located in a dark box as the potential was applied. In undiluted calf serum, ultra-
low detection limits between 110 and 500 fg/mL were achieved for PSA, CD-14, GOLM-1, 
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IGFBP-3, IGF-1, PF-4, VEGF-D and PSMA within 25 min. The 3D-printed immunoarray 
exhibited accurate recovery percentages of approximately 100 ± 14%, while also achieving 
negligible antibody cross-reactivity between all eight proteins. The 3D-printed immuno-
array could distinguish between non-PCa and PCa patients. Additionally, the authors 
suggested that this immunoarray could potentially be used to distinguish between clini-
cally insignificant and significant PCa patients. However, more tests using human serum 
samples are needed to ensure that this is firmly concluded. Overall, it was deduced that 
the easy-to-use immunoarray is cost-effective, with xPOCT characteristics, especially 
when required in low-resourced environments [52]. 
 
Figure 7. A 3D-printed immunoarray with touch screen user interface to control ECL measurements. 
A microfluidic array connected to a micropump is shown with dye-filled reagent chambers and 
graphite detection chip. Inset figures show multiple immunoassay steps along with messages to 
inform the user. Reproduced with permission from ref [52]. Copyright 2018 American Chemical 
Society. 
3.1.2. Surface-Enhanced Raman Scattering 
Surface-enhanced Raman scattering (SERS) is another optical detection technique 
used to demonstrate the analysis of multiple protein markers because it is non-destruc-
tive, photostable and sensitive to the assessment of specific biomarkers [109]. SERS has 
been developed to increase the intensity of Raman scattering by a factor of up to 1012 [110]. 
The enhanced intensity is enough to measure sufficiently the changes in plasmonic reso-
nance of molecules adsorbed singularly on or near roughened noble metal surfaces, such 
as gold (Au) or silver (Ag) [98,111–114]. Zhou et al. developed a multiplex SERS-based 
immunoassay that detected PSA, PSMA and hK2 [60]. A sandwich immunoassay was 
formed using silver nanoparticles (AgNPs) as the platform for the immobilization of the 
capture antibodies. The SiC/Ag/Ag-NPs SERS substrate was attached to the detecting an-
tibodies to bind to the respective antigen. Using linear support vector machine (SVM) al-
gorithms, the limits of detections for PSA, PSMA, and hK2 were 0.46 fg/mL, 1.05 fg/mL 
and 0.67 fg/mL, respectively. Additionally, they achieved 70% accuracy in distinguishing 
between PCa patients with BHP and healthy patients. The accuracy of the diagnosis of 
healthy or BHP patients was 75% and 60%, respectively. In comparison, 50% accuracy was 
achieved to detect only the serum level of PSA. This SERS platform could be used for 
diagnosing PCa patients in terms of providing clinical xPOCT. 
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Additionally, Chen et al. has developed a SERS-based vertical flow assay (VFA) for 
the detection of PSA, carcinoembryonic antigen (CEA) and α-1-fetoprotein (AFP) [115]. 
CEA and AFP are cancer protein biomarkers that are not specific to PCa as they can be 
found in a variety of cancer types [116]. Normally, conventional point-of-care VFAs are 
paper-based gold-conjugated immunoassays and gold colloids. Instead, Raman dyes 
(RDs) encoded core-shell SERS nanotags were used as detection probes to improve the 
precision and sensitivity during detection measurements. The authors have achieved de-
tection limits of 0.37, 0.43, and 0.26 pg/mL for PSA, CEA and AFP respectively. It was 
concluded that this platform could be used as a xPOCT device, in conjunction with a port-
able Raman instrumentation, as a benchtop device in a hospital or GP clinic. This is be-
cause the SERS immunoassay provides highly sensitive biomarker detection meanwhile 
the VFA platform enables faster operation and simple analysis [115]. 
In addition to this, Xiao et al. demonstrated the sensitivity and portability of a multi-
plex SERS-based immunoassay using an LFIA reader to also evaluate AFP, CEA and PSA 
[114]. The LFIA reader was 3D printed and could be incorporated between a choice of two 
multi-channel LFIA reaction columns, as shown in Figure 8. Type 1 of the LFIA column 
(single-sample, multimarker reaction column) involved the use of a liquid drainage grove 
which runs the same solution on all eight connected channels. Whereas the Type 2 LFIA 
column (multisample, single-marker reaction column) consisted of sample holders for 
each lateral strip, making it possible to detect a specific cancer biomarker on different 
strips within the same column. In Figure 9, either Type 1 or Type 2 of the LFIA column 
was placed on the holder inside the reader and operated via the stepper motor and two-
axis translated stage to rotate back and forth and move up and down at specific times. 
Therefore, it was possible to perform SERS detection for each strip using the Raman probe 
to focus on the test and control lines, as targeted immunocomplexes were formed. In ad-
dition, the photoelectric switch corrected the position of each observation window to en-
sure that measurements were carried out in an orderly manner. The SERS nanotags used 
were composed of gold nanorods (AuNRs) and a Raman reporter molecule, 5,5′-dithiobis-
(2-nitrobenzoic acid) (DTNB), to match the laser wavelength of the excitation (785 nm). 
These AuNR−DTNB plasmonic NPs were further functionalized with specific detection 
antibodies and BSA, which provided biocompatibility and stability. The Type 1 column 
was used for evaluating the LFIA reader’s specificity in which five antibodies were im-
mobilized on the control line of the strip. This involved the use of all three cancer bi-
omarkers’ antibodies as well as the antibodies specific to interfering inflammation bi-
omarkers, C-reactive protein (CRP) and Procalcitonin (PCT). The test line was found to 
visually darken only when the target cancer biomarker was captured, regardless of the 
addition of interference protein biomarkers. The visual interpretation of the test lines also 
corresponded to the SERS signal detected. In addition, uniformity tests have shown that 
the device produces uniform, reliable and stable results. When using the Type 2 column, 
the overall process, which involved 20 repeats for each of the eight strips used, took place 
within 18 min. Detection limits of 0.01 ng/mL in PBS solution for all three cancer bi-
omarkers were achieved, which was 1000 times more sensitive than that acquired for vis-
ual signals. Lastly, clinical serum samples consisting of either positive or negative samples 
were correctly detected for all three cancer biomarkers using the Type 2 LFIA columns. 
The results of the clinical sample were also well correlated with ECL and demonstrated 
higher sensitivity compared to the ELISA analysis. Overall, the SERS-based LFIA has the 
potential to be used as a xPOCT device in multiple applications including the diagnosis 
and treatment management of PCa patients. 
An overview of recent developments of optical biosensors for multiplexed detection 
of PCa protein biomarkers is presented on Table 2. 




Figure 8. Detailed figure of the two types of multi-channel LFIA reaction columns; (a) Single-sam-
ple, multimarker reaction column (Type 1); (b) cross-sectional view of Type 1 LFIA column; (c) mul-
tisample, single-marker reaction column (Type 2); (d) Type 2 column’s cross-sectional view. Repro-
duced with permission from ref [114]. Copyright 2020 Elsevier. 
 
Figure 9. Illustration of portable SERS-based LFIA reader; (a) LFIA strip and (b) multi-channel LFIA 
reaction column, (c) Detailed schematic of the SERS-based LFIA reader and (d) the completed view 
of the portable reader. Reproduced with permission from ref [114]. Copyright 2020 Elsevier. 
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Table 2. Overview of recent developments of optical biosensors for multiplexed detection of PCa protein biomarkers with 
indication of tests done with PCa patient samples. 
Technique Biomarkers Sensor Surface Modification Detection Label 
Linear Detection 
Range 







Ab1 (monoclonal tPSA cap-
ture antibody) 
For fPSA: Ab2/MQB625 
– 
fPSA: 0.009 ng/mL 
[95]  






Ab1 Ab2/poly HRP 
PSA: 0.5 pg/mL–5 
ng/mL * 0.5 pg mL−1 for both PSA 
and PF-4 [99]  
PF-4 






For fPSA: Ab2 (Anti-fPSA)/HRP 
For fPSA glycans: biotinylated 
SNA/SA-HRP 
fPSA: 0.01 to 50 
ng/mL 
fPSA: 0.5 ng/mL 
[100]  
fPSA glycans: 3 to 50 
ng/mL 







Ab1 (monoclonal tPSA cap-
ture antibody) 
For tPSA & fPSA: Ab2/HRP 
– 
fPSA: 0.03 ng/mL 
[102]  








PSA: 1 pg/mL–10 
ng/mL * 
PSA: 1 pg/mL 
[105]  
IL-6 
(PSA and IL-6 conjugated to the 
same RuBPY-SiNPs) 
IL-6: 0.1 pg/mL–2 
ng/mL * 








PSA: 100 fg/mL–40 
pg/mL (100 fg/mL–10 
ng/mL *) 
PSA: 100 fg/mL 
[106]  
IL-6 
(PSA and IL-6 conjugated to the 
same RuBPY-SiNPs) 
IL-6: 0.5 fg/mL–10 
fg/mL (0.5 fg/mL–1 
ng/mL *) 







For Label 1 (PSA & IL-6) and 
Label 2 (PSMA & PF-4): 
Ab2/RuBPY-SiNP 
PSA: 100 fg/mL–1 
ng/mL * 
PSA: 50 fg/mL 
[107]  
PSMA 
PSMA: 100 fg/mL–10 
ng/mL * 
PSMA: 100 fg/mL 
PF-4 
PF-4: 100 fg/mL–5 
ng/mL * 
PF-4: 10 fg/mL 
IL-6 
IL-6: 100 fg/mL–5 
ng/mL * 







For all proteins: 500 
fg/mL–10 ng/mL * 
PSA: 300 fg/mL 
[108]  PSMA PSMA: 535 fg/mL 







For Label 1 (PSA & PSMA), la-
bel 2 (VEGF-D & PF-4), label 3 
(CD-14 & IGF-1), and label 4 
(GOLM-1 & IGFBP-3): 
Ab2/RuBPY-SiNP 
For all proteins: 0.5 
pg/mL–10 ng/mL 


















PSA: 0.46 fg/mL 
[60]  PSMA 
PSMA: 1.05 fg/mL–
113.4 ng/mL 











For PSA: AuNBA-Ag/Ab2 
PSA: 1 pg/mL–10 
µg/mL 
PSA: 0.37 pg/mL 
[115]  
CEA For CEA: Au4-MB-Ag/Ab2 
CEA: 10 pg/mL–1 
µg/mL 
CEA: 0.43 pg/mL 
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AFP For AFP: Au4-NBT-Ag/Ab2 
AFP: 10 pg/mL–1 
µg/mL 






Ab1 AuNRs-DTNB/Ab2/BSA - For all proteins: 10 pg/mL [114] CEA 
AFP 
Abbreviations: 4-MB = 4-Mercaptobenzonitrile, 4-MBA = 4-mercaptobenzoic acid, 4-NBT = 4-nitrobenzenethiol, Ab1 = cap-
ture antibody, Ab2 = detection antibody, Ab3 = secondary detection antibody, AFP = α-1-fetoprotein, AgNP = silver nano-
particles, ALP = alkaline phosphatase, Apt = Deoxyribonucleic acid aptamer, BSA = Bovine Serum Albumin, CD-14 = 
Cluster of differentiation-14, CEA = Carcinoembryonic antigen, CL = Chemiluminescence, cPSA = complexed PSA, DTNB 
= 5,5′-dithiobis-(2-nitrobenzoic acid), ECL = Electrochemiluminescence, fPSA = free PSA, GOLM-1 = Golgi membrane pro-
tein-1, GOPTS = (3-Glycidyloxypropyl) trimethoxysilane, hK2 = Human kallikrein 2, HRP = horseradish peroxidase, IGF-
1 = Insulin-like Growth Factor-1, IGFBP-3 = Insulin-like Growth Factor binding protein-3, IL-6 = Interleukin-6, MQB = 
magnetic-quantum dot nanobeads, NBA = Nile Blue A, PF-4 = Platelet Factor-4, PSMA = Prostate-specific membrane anti-
gen, RuBPY-SiNP = Tris(bipyridine)ruthenium(II) chloride, SA = Streptavidin, SERS = Surface-enhanced Raman scattering, 
SiNP = silica nanoparticles, SNA = Sambucus nigra, SWNCT = single-wall carbon nanotube, tPSA = total PSA, VEGF-D = 
Vascular endothelial growth factor. * Dynamic detection ranges. 
3.2. Electrochemical Detection Methods 
3.2.1. Amperometric Techniques 
Amperometry focuses on measuring the resulting current as a constant potential is 
applied within the electrochemical cell [117,118]. Amperometric detection was used by 
Chikkaveeraiah et al. to achieve multiplexed detection of PSA, PSMA, PF-4 and IL-6 [68]. 
Single-wall carbon nanotube forests (SWCNF) have modified the four working electrodes. 
Each working electrode was then immobilized with one of the four respective capture 
antibodies. After the capture antibodies bound to the protein biomarkers, they are at-
tached to detection antibodies to form a sandwich immunocomplex. PSA and PSMA de-
tection antibodies have been modified with HRP, whereas streptavidin-HRP (SA-HRP) 
labels were used to modify the PF-4 and IL-6 biotinylated detection antibodies. Approxi-
mately 16 SA-HRP labels were attached to a single antibody in order to achieve a higher 
sensitivity while detecting an electrochemical signal. This significantly amplified the am-
perometric signal detected during binding events for PF-4 and IL-6, as their protein dy-
namic concentration ranges are lower compared to PSA and PSMA. In the presence of the 
mediator, hydroquinone, HRP catalyzed H2O2 producing specific amperometric reduc-
tion peaks at a voltage of −0.3 V, while detecting different concentrations of the respective 
biomarker. This resulted in detection limits of 1, 10, 1 and 0.03 ng/mL for PSA, PSMA, PF-
4 and IL-6 in diluted calf serum, respectively [68]. 
Moreover, using amperometric detection, Chikkaveeraiah et al. were able to achieve 
lower detection limits of 0.23 pg/mL and 0.30 pg/mL for PSA and IL-6, respectively, in 
diluted calf serum using a PDMS microfluidic-based platform [15]. Capture antibodies 
were immobilized on eight working electrodes that had previously been deposited with 
glutathione-decorated gold nanoparticles (GSH-AuNPs). In this study, superparamag-
netic nanoparticles conjugated with specific detection antibodies (~90,000 per nanoparti-
cle) and HRP labels (~20,000 labels per nanoparticle) were used for the off-line capture of 
the PCa protein biomarkers in calf serum solution. Using a syringe, the modified super-
paramagnetic nanoparticles solution flowed to the respective electrode surfaces. Follow-
ing this, hydroquinone and H2O2 solutions were introduced to initiate an electrochemical 
reaction that could be detected amperometrically. Additionally, the biosensor platform 
was well correlated with ELISA in the use of patient serum samples, while also dramati-
cally reducing manufacturing costs compared to conventional systems. A faster total anal-
ysis time (1.15 h) was achieved, and a minute sample volume (5 µL) was required to obtain 
highly sensitive and specific results. 
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Sharafeldin et al. used an offline capture method within a microfluidic electrochem-
ical immunoassay to simultaneously detect PSA and PSMA in undiluted calf serum [119]. 
In this case, the working electrodes were modified with iron oxide nanoparticles (Fe3O4 
NPs) on graphene oxide nanosheets, which were then decorated with specific capture an-
tibodies using 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride 
(EDC)/N- hydroxysulfosuccinimide (NHS) chemistry. The microfluidic system was used 
to introduce serum samples to initiate the respective binding events of the immobilized 
capture antibodies to their specific protein biomarker. The bound protein biomarkers 
were magnetically separated from the unbound biomarkers in the sample. From which 
the solution flowed through the microfluidic system to the detection chamber, where the 
detection antibodies attached to their respective protein biomarker. Fe3O4 NPs performed 
similarly to HRP, capable of catalyzing hydrogen peroxide to produce an amperometric 
signal. Detection limits of 15 and 4.8 fg/mL were achieved for PSA and PSMA, respec-
tively. The results were comparable to previous studies using detection antibodies modi-
fied with magnetic beads and HRP. Moreover, the immunoassay was well correlated with 
the ELISA method when using patient serum samples. 
Mercer et al. developed a microfluidic immunoarray platform, powered by a pro-
grammable Arduino microcontroller, capable of detecting eight PCa protein biomarkers 
simultaneously, negating the need for a desktop or laptop [55]. Using the protocol de-
scribed by Otieno et al. [120], the carbon working electrodes were modified with a layer 
of poly(diallyldimethylammonium chloride) (PDDA), followed by GSH-AuNPs. The mod-
ified electrodes were then immobilized with sandwich immunocomplexes, consisting of 
MP-Ab2-HRP conjugates as the detection antibodies. The immunoarray exhibited two am-
perometry protein detection chambers, as depicted in Figure 10. The Arduino microcontrol-
ler powered the automated processes of the microfluidic system, incorporating several com-
ponents, including valve actuators, a syringe pump, magnetic stirrers and an electronic dis-
play. Amperometric detection limits of 140, 90, 15, 13, 130, 150, 90 and 15 pg/mL were 
achieved in serum for PSA, VEGF-D, erythroblast transformation specific related gene 
(ERG), IGF-1, CD-14, IGFBP-3, pigment epithelium-derived factor (PEDF-1) and GOLM-1, 
respectively, within 30 min [55]. ERG is over-expressed in patients with PCa and contributes 
to PCa progression [2,121], whereas PEDF is suggested to exhibit down-regulated serum 
levels in PCa patients, acting as an angiogenesis inhibitor. Overall, the microfluidic immu-
noarray platform demonstrated the possibility of being used as a clinical xPOCT device, 
such as a hospital clinic, suitable for diagnosing and staging PCa progression [55]. 




Figure 10. Illustration of an automated microfluidic immunoarray platform, featuring; (a) Arduino 
Uno microcontroller, (b) syringe pump, (c) sample injector, (d) servo-actuated valves, (e) capture 
chambers and magnetic stirrers, (f) detection chambers, and (g) LCD displays. Reproduced with 
permission from ref [55]. Copyright 2019 Wiley-VCH Verlag. 
3.2.2. Voltammetric Techniques 
Voltammetry is a sub-class of amperometry which measures the flow of electrons as 
a varied potential is swept across the working electrode [118,122]. Tang et al. devised a 
cost-effective electrochemical microfluidic immunoarray containing eight miniaturized 
ports in order to achieve 256 individual working microelectrodes, simultaneously detect-
ing PSA alongside PSMA, IL-6 and PF-4, within one hour [123]. It was noted that each 
immunoarray contained 32 sensors, which were divided into four sections, for the respec-
tive protein biomarkers, as depicted in Figure 11. For simplicity during the DPV measure-
ments, each 32-sensor array had its own on-chip reference and counter electrodes. SAM 
modified electrodes were attached to the hydrophobic wells to prevent cross-contamina-
tion of the antibodies on their respective surface during immobilization. Furthermore, the 
SAM layer, composed of mercaptopropionic acid (MPA), was immobilized on the elec-
trode surface, followed by the attachment of capture antibodies using EDC/NHS chemis-
try. An off-line capture protocol was established within a separate reservoir to attach dif-
ferent protein concentrations to their respective biotinylated detection antibodies that 
were functionalized in conjunction to biotinylated HRP labels (~8500 HRP labels per na-
noparticle onto streptavidin coated magnetic nanoparticles). From which bound detection 
antibodies were introduced to the microelectrodes using the microfluidic system by 
means of an inlet tube connected to the reagent reservoir. To load the reagents into the 
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microfluidic system, a syringe was connected to the outlet tubing of all eight of the im-
mune arrays, effectively detecting the protein biomarkers. Hydroquinone and H2O2 were 
introduced to the microfluidic system for the measurement of differential pulse voltam-
metry (DPV). For six replicates of eight protein concentrations, the limits of detections for 
PSA, PSMA, PF-4 and IL-6 in diluted calf serum were 2, 0.15, 0.1 and 0.05 pg/mL, respec-
tively. This immunoarray demonstrated high-throughput detection of multiple protein 
biomarkers at a low cost, using simple but highly sensitive equipment. 
 
Figure 11. An electrochemical microfluidic immunoarray: (A) 256 individual working microelec-
trodes configuration; (B) 8 microfluidic immunoarrays are connected via miniaturized 8-port man-
ifold; (C) molded PDMS microfluidic channel, and (D) deconstructed view of the integrated micro-
fluidic immunoarray. Reproduced with permission from ref [123]. Copyright 2016 American Chem-
ical Society. 
Pan et al. also used DPV to detect VEGF and PSA from serum samples of PCa patients 
simultaneously [124]. A three-step fabrication process involving metal-film deposition, 
photolithography and metal etching was used to develop the two-electrode system con-
sisting of gold working and counter electrodes on a glass slide. For the completion of the 
three-electrode system, a separate silver/silver chloride (Ag/AgCl) reference electrode 
such as . The graphene oxide modified working electrode was immobilized with VEGF-
specific DNA aptamers. The electrode surface was then introduced with the VEGF solu-
tion. Similarly, to the CL protocol of Jolly et al. [100], detection antibodies were then in-
troduced to the surface of the sensor. However, PSA and VEGF were analyzed on the 
same sensor surface instead of using parallel microchannels. Detection antibodies for PSA 
and VEGF (anti-PSA and anti-VEGF) were functionalized onto modified poly-L-lactide 
nanoparticles (PLLA NPs) and then introduced to the electrode surface. In which the anti-
VEGF antibodies on the PPLA NPs bound to the VEGF protein immobilized on the elec-
trode surface to form a sandwich-based assay. After this, the biosensor was immersed in 
PSA solution that also bound to the anti-PSA antibodies present on the PLLA NPs. This 
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resulted in detection limits of 50 pg/mL and 1 ng/mL for VEGF and PSA, respectively, and 
highly correlated with ELISA in the evaluation of samples from early staged PCa patients. 
Alternatively, square wave voltammetry (SWV) was used by Akbari Jonous et al. to 
simultaneously detect tPSA and fPSA, using a carbon working electrode with a sandwich-
based format [125]. Reduced graphene oxide and AuNPs were used to modify both the 
capture and detection monoclonal antibodies. This significantly magnified the voltam-
metric detection signal as nanomaterials increased the carbon electrode’s conductivity, 
resulting in faster electron transfer rates. Detection limits of 0.2 and 0.07 ng/mL were de-
termined for tPSA and fPSA, respectively. The biosensor was well correlated with the 
standard CL test using patients’ serum samples. The authors suggested that it could be 
used as a PCa diagnostic POCT device. Additionally, Liu et al. have developed a flexible 
PDMS 8 × 8 electrode immunoarray for multiplex electrochemical detection of PSA, PSMA 
and IL-6, as shown in Figure 12 [69]. The Au electrodes were used to form a sandwich-
based immunosensor, initially immobilized with capture antibodies functionalized with 
magnetic beads. In addition, detection antibodies were functionalized with AuNRs deco-
rated with HRP (HRP-Ab2-AuNRs). Cyclic voltammetry (CV) was used to measure the 
resulting current with low detection limits of 0.1, 0.8 and 0.005 ng/mL determined for PSA, 
PSMA and IL-6, respectively. The authors concluded that the microchip could be used as 
a xPOCT device, exhibiting strengths due to its versatility, in terms of fabrication, modi-
fication processes, and storage. It is also less likely to be damaged compared to rigid glass 
substrates used for the fabrication of biosensor platforms. 
 
Figure 12. A flexible PDMS 8 × 8 electrode immunoarray; (A) Schematic of preparing the microchip 
along with the sensor surface modifications; (B) Illustration of the detection of PSA, PSMA and IL-
6, with control measurements, in one microchannel. Reproduced with permission from ref [69]. 
Copyright 2014 American Chemical Society. 
3.2.3. Impedimetric Techniques 
Impedance-based biosensors are label-free and highly sensitive electrochemical de-
tection techniques that reduce the number of reagents required and hence reduce the over-
all analysis time [4,94]. Electrical impedance spectroscopy evaluates the capacitive or re-
sistive behavior established from the charges separated at the electrode-electrolyte inter-
face [94,117]. Impedance-based biosensors require the application of a low sinusoidal ac 
voltage (typically 5–10 mV) at a specific frequency [94,118]. The voltage perturbation is 
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used to demonstrate the biological binding events that occur at the surface of the electrode 
by evaluating the charge flow [117]. The charge flow or electrical signal can be modeled 
using the Randles equivalent circuit, as depicted in Figure 13 [126]. The charge resistance 
at the interfacial layer of the working electrode is known as the charge transfer resistance, 
RCT. Within the circuit, the RCT is parallel to the capacitance, CDL, which describes the elec-
trode-electrolyte interface’s electrical double layer. Additionally, in series to the RCT, W 
represents the Warburg diffusion coefficient and RSOL is to demonstrate the uncompen-
sated resistance of the solution [127]. Impedance data are generally represented using 
Nyquist or Bode plots [128]. 
 
Figure 13. Randles equivalent circuit to the model the charge flow during electrochemical impedance 
spectroscopy detection, RCT represents the charge transfer resistance, RSOL denotes the uncompensated 
solution resistance, CDL represents the capacitance and W signifies the Warburg diffusion coefficient. 
Chiriacò et al. designed an impedimetric dual-labeled microfluidic biosensor based 
on the conventional ELISA method [129]. The PDMS-based microfluidic system had two 
chambers, as shown in Figure 14. Each chamber consisted of modified SAM electrodes 
with anti-fPSA and anti-tPSA antibodies, respectively, using EDC/NHS chemistry. Anti-
tPSA capture antibodies could be attached to both biomarkers, fPSA and cPSA, both of 
which have the same epitope recognition on their surfaces. This provided accurate %fPSA 
measurements, therefore, in order to diagnose and also to distinguish PCa patients from 
other conditions. The fPSA and cPSA solutions flowed into their respective chambers. A 
solution containing the electrochemical redox probe, [Fe(CN)6]3–/4–, was then used during 
electrochemical impedance spectroscopy (EIS) measurements. It was found that following 
the functionalizing of the electrode with the SAM layer and subsequent binding of the 
antibodies to their respective biomarker, the RCT value increased. The electron transfer 
from the bulk solution to the working electrodes was therefore restricted. Sensitive detec-
tion limits of approximately 1 ng/mL in PBS solution were achieved for both biomarkers. 
Additionally, the authors were able to simultaneously detect fPSA and cPSA in order to 
evaluate %fPSA. If the %fPSA is lower than cut-off level (<25%), this determined that the 
patient has PCa. Using two solutions with fixed %fPSA (50 and 20%), the biosensor was 
able to distinguish between the two solutions, calculating the %fPSA to be 42% and 19%, 
respectively. This platform therefore has the potential to distinguish BHP patients from 
PCa patients. Thus, using this simple fabrication process, the overall analysis time has not 
only been shortened compared to the conventional ELISA method, but is also cost-effec-
tive using a simple manufacturing process. 
Additionally, Pihíková et al. reported a label-free impedimetric biosensor capable of 
detecting PSA and PSA glycans at the same time [130]. As mentioned previously, research 
has been conducted on how changes in the conformation of PSA glycosylation can be 
linked to PCa progression. Primarily, the capture antibodies were immobilized to the 
SAM layer, composed of 11-mercaptoundecanoic acid and 6-mercapto-1-hexanol, on the 
surface of the sensor, using EDC/NHS chemistry. This allowed the PSA to attach to the 
capture antibodies. Mass spectrometry is typically used for the analysis of PSA glycans. 
However, the lectin, SNA, was used by the impedimetric biosensor to detect glycosylated 
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PSA forms. The lectins specifically attached to the terminal sialic acid present on PSA, to 
form a sandwich format. [Fe(CN)6]3–/4– was used as an electroactive redox probe for EIS 
measurements. Sensitive detection limits of 4 aM (about 0.13 fg/mL) were achieved for 
both PSA and PSA glycans. 
 
Figure 14. (a) Schematic representation of PSA antigens-related (cPSA and fPSA) and (b) device 
composed of two chambers for detecting the antigens: (c) one chamber is functionalized with anti-
fPSA antibodies (Chamber 1) and the other one with anti-tPSA antibodies (Chamber 2). Reproduced 
with permission from ref [129]. Copyright 2013 Royal Society of Chemistry. 
Diaz Fernandez et al. developed a dual aptamer-based impedimetric biosensor, com-
prised of two adjacent nanostructured gold electrodes that detected both PSA and glyco-
sylated PSA (PSAG-1) using anti-PSA and PSAG-1 aptamers [131]. A SAM layer of 11-
amino-1-undecanothiol was applied to the gold working electrodes. Mercaptohexanol 
(MCH) was used as a blocking agent or backfiller before AuNPs were introduced to im-
mobilize the SAM layer. After that, another SAM layer was applied to the surface, con-
sisting of a 1:100 ratio of the relevant aptamer (anti-PSA/PSAG-1) and MCH. In diluted 
serum, the aptasensor had detection limits of 0.64 and 0.26 ng/mL for PSA and PSAG-1, 
respectively. When impedimetric detection with the PSAG-1 aptamer was used to detect 
recombinant PSA (rPSA), the signal rise was lower than when detecting human PSA 
(hPSA). When using the anti-PSA aptamer to detect both rPSA and hPSA, a similar signal 
increase (96%) was seen between the two PSA proteins. As a result, PSAG-1 has been con-
firmed as the aptamer that can recognize PSA’s glycosylated sites. Human serum albumin 
was shown to have a very little interference, indicating that this platform is overall selective 
to PSA. Furthermore, the glycan score (GS) was calculated using clinical serum samples. 
The GS is the ratio between the concentration of the glycosylated PSA (detected with PSAG-
1 aptamer) to tPSA (detected with anti-PSA aptamer), multiped by 100. In comparison to 
benign and healthy patients (values between 22 and 37), a clear correlation was discovered 
between the GS and the known diagnosis of PCa patients (values between 82 and 86), as 
illustrated in Figure 15, rather than looking at the concentrations of the analytes inde-
pendently. The authors came to the conclusion that this platform might be used to im-
prove patient PCa diagnosis while also minimizing the number of unnecessary biopsies 
performed. 
An overview of recent developments of electrochemical biosensors for multiplexed 
detection of PCa protein biomarkers is presented on Table 3. 
 




Figure 15. Illustration of anti-PSA and PSAG-1 aptamers used in the dual aptamer-based impedimetric biosensor to detect 
PSA and PSA glycans. Using clinical serum samples, the EIS measurement were used to measure the glycan score (GS), 
which is the ratio between the concentration of the glycosylated PSA (detected with PSAG-1 aptamer) to tPSA (detected 
with anti-PSA aptamer), multiped by 100. According to the graphical data, the GS can be used to distinguish known PCa 
patients from benign and healthy patients. Reproduced with permission from ref [131]. Copyright 2020 Elsevier. 
Table 3. Overview of recent developments of electrochemical biosensors for multiplexed detection of PCa protein bi-
omarkers with indication of tests done with PCa patient samples. 
Technique Biomarkers Sensor surface modification Detection Label 
Linear Detection 
Range 






For PSA & PSMA: 
SWCNF/Ab1 
 
For PF-4 & IL-6: 
SWCNF/Ab1 
For PSA & PSMA: Ab2/HRP 
 
For PF-4 & IL-6: Ab2/SA-HRP 
PSA: 1–40 ng/mL PSA: 1 ng/mL 
[68]  
PSMA PSMA: 10–250 ng/mL PSMA: 10 ng/mL 
PF-4 PF-4: 1–40 ng/mL PF-4: 1 ng/mL 
IL-6 
IL-6: 50–500 pg/mL 
(biphasic with better 
sensitivity below 350 
pg/mL) 






GSH-AuNPs/Ab1 MP/Ab2/HRP – 
PSA: 0.23 pg/mL 
[15] 






ERGO/Ab1 Ab2/Fe3O4 NPs/GO 
PSA: 61 fg/mL–3.9 
pg/mL * 
PSA: 15 fg/mL 
[119]  
PSMA PSMA: 9.8 fg/mL–10 
pg/mL * 

































GOLM-1: 15 pg/mL  






PSA: 2 pg/mL–200 
ng/mL * 
0.05–2 pg/mL [123]  
PSMA 
PSMA: 0.15 pg/mL–
15 ng/mL * 
PF-4 
PF-4: 0.1 pg/mL–10 
pg/mL * 








For VEGF & PSA: Ab2/PPLA 
NPs, where Ab2 is a mixture of 
anti-VEGF and anti-PSA anti-
bodies 
– 
PSA: 1 ng/mL 
[124]  






GO/AuNPs/Ab1 GO/AuNPs/Ab2 – 
tPSA: 0.2 ng/mL 






PSA: 0.1–10 ng/mL PSA: 0.1 ng/mL 
[69]  PSMA PSMA: 0.8–400 
ng/mL 
PSMA: 0.8 ng/mL 
IL-6 IL-6: 5–1000 pg/mL IL-6: 0.005 ng/mL 
EIS 
fPSA 




SAM (MUA-MCH)/Ab1 SNA 4 a.m. to 40 nM 
PSA: 4 aM 
[130]  
PSA glycans 
PSA glycans: down to 4 









PSA: 0.64–62.5 ng/mL 




62.5 ng/mL * 
PSA glycans: 0.26 ng/mL 
Abbreviations: 2-ME = 2-mercaptoethanol, Ab1 = capture antibody, Ab2 = detection antibody, Amp = Amperometry, Apt = 
DNA aptamer, AuNPs = Gold nanoparticles, AuNRs = Gold nanorods, AUT = 11-amino-1-undecanothiol, CD-14 = Cluster 
of differentiation-14, CV = Cyclic Voltammetry, DPV = Differential Pulse Voltammetry, EIS = Electrical Impedance Spec-
troscopy, ERG = Erythroblast transformation specific related gene, ERGO = electrochemically reduced graphene oxide, 
Fe3O4 NPs = Iron oxide nanoparticles, fPSA = Free PSA, GO = Graphene oxide, GOLM-1 = Golgi membrane protein-1, GSH 
= Glutathione, HRP = horseradish peroxidase, IGF-1 = Insulin-like Growth Factor-1, IGFBP-3 = Insulin-like Growth Factor 
binding protein-3, IL-6 = Interleukin-6, MB = magnetic beads, MCH = 6-mercapto-1-hexanol, MP = magnetic nanoparticles, 
MPA = mercaptopropionic acid, MUA = 11-mercaptoundecanoic acid, PDDA = poly(diallyl dimethylammonium chloride), 
PEDF = Pigment epithelium-derived factor, PF-4 = Platelet factor-4, PPLA NPs = Poly-L-lactide nanoparticles, PSA = Pros-
tate-Specific Antigen, PSMA = Prostate-specific membrane antigen, SA = streptavidin, SAM = self-assembly monolayer, 
SNA = Sambucus nigra, SWCNF = single-wall carbon nanotube forests, SWV = Square Wave Voltammetry, tPSA = Total 
PSA, VEGF = Vascular endothelial growth factor. * Dynamic detection ranges. 
3.3. Potential Companion Diagnostic Devices Using Integrated Biosensor Systems 
Overall, the research prototypes discussed in this review have the potential to be just 
as accurate as traditional protein detection methods, and they can be implemented in con-
junction with the ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and Ro-
bust, Equipment-free, and Delivered to those who need it) strategy of companion diag-
nostics devices [132,133]. Thus, considerable attention has been dedicated to the creation 
of cost-effective integrated biosensor systems, such as the application of microfluidic sys-
tems, while also considering multiplexed detection techniques, as stated above. Microflu-
idic system integration is a crucial technique to explore for clinical usage by end users, as 
it can enable high-throughput detection while requiring smaller sample amounts, and 
possible automated control [89,134]. In addition, microfluidic systems can incorporate im-
portant steps performed in a clinical laboratory setting, such as sample preparation, mo-
lecular recognition, and signal amplification procedures (so-called lab-on-chip devices), 
negating the need for expensive specialist equipment or skilled professionals [135]. 
Key fabrication technologies used to detect PCa protein biomarkers included paper-
based techniques, polymer (plastic-based) microfabrication, and the usage of microarrays 
[118]. When incorporating multiplexing approaches to either optical or electrochemical 
Sensors 2021, 21, 5023 26 of 32 
 
 
detection methods, each fabrication technology has some limitations, which can have an 
impact on translating prototypes into clinical utility that is appropriate for end users 
[89,136]. Because electrical instrumentation is difficult to incorporate, paper-based tech-
niques such as LFIAs are more compatible with optical measurements. Although polymer 
(plastic-based) microfabrication designs are more efficient for electrochemical detection 
approaches, such platforms are not mass-produced in terms of electronics integration. As 
a result, the time and expense required to complete such processes significantly escalates 
[136]. Furthermore, increasing the number of spatially separated detection sites or regions 
for PCa protein biomarkers necessitates the inclusion of additional components such as 
more controls, valves, and detection/capture chambers, resulting in a complicated fabri-
cation process. On the other hand, simple designs without controlled sites or regions 
could lead to cross-reactivity of sample solutions introduced to the biosensor system, re-
sulting in unreliable detection results. Meanwhile, when using sandwich immunocom-
plexes as the surface chemistry, the inclusion of additional labels will necessitate addi-
tional washing steps in between incubation steps and/or detection measurements. Label-
free surface chemistries, on the other hand, may impair detection sensitivity for certain 
PCa protein biomarkers with low serum concentrations. As a result, a compromise must 
be established between the integrated biosensor system’s complexity and the multiplexed 
detection approach [20,89]. 
Due to being mass-produced internationally at a cheap cost and being compact/port-
able, printed circuit boards (PCBs) could alleviate some of the issues faced with plastic-
based biosensors for electrochemical biosensor systems [136,137]. Furthermore, PCBs have 
long been integrated with both electronic and microfluidic devices, requiring low sample 
volumes and coinciding with the ASSURED approach to xPOCT (lab-on-PCB approach) 
[136]. Therefore, multiplexing techniques combined with PCBs can potentially help secure 
consistent clinical outcomes for PCa patients that are highly sensitive and specific. 
4. Conclusions and Future Perspectives 
We summarized some of the emerging PCa protein biomarkers reported to date that 
may be relevant for PCa diagnosis, prognosis, and treatment monitoring, in conjunction 
with the widely known biomarker PSA. Although several markers have been recognized, 
these are still yet to be validated as PCa biomarkers [138]. In addition, this review looked 
at recent developments in miniaturized biosensor systems using optical and electrochem-
ical detection techniques, to detect multiple PCa protein biomarkers simultaneously. Such 
miniaturized biosensor surfaces have been modified using a variety of labels or nano-
materials, such as enzymes, metallic nanoparticles, or graphene sheets, in order to achieve 
systems with multiplexing capacities. In addition, some of the biosensor platforms men-
tioned have been integrated with a microfluidic system, allowing the implementation of 
complex functions as seen in clinical laboratories (lab-on-a-chip approach). Thus, effec-
tively achieving sensitive results while using smaller reagent and sample volumes in a 
reliable and accurate manner that is comparable to conventional clinical laboratory per-
formance [139]. Additionally, the manufacture of 3D-printing microfluidic systems pro-
vides cost-effective and simple fabrication processes compared to conventional methods 
[52,99,108,139]. Moreover, analyzed results were well correlated with conventional meth-
ods, such as ELISA single-analyte kits. However, more work is needed to translate bio-
sensor detection platforms into commercially available xPOCT devices in order to deliver 
highly cost-effective and sensitive results that leads to better management of PCa treat-
ment in near-patient settings in a timely manner [20]. This would allow the use of multi-
plexed companion diagnostic devices as alternatives to conventional PCa diagnostic tech-
niques, such as DRE, transrectal ultrasonography (TRUS), positron emission tomography 
(PET) and/or magnetic resonance imaging (MRI) [24]. 
Overall, recent developments showed that modifications to the surface of the biosen-
sor can provide efficient and sensitive multiplexed protein detection. However, further 
research is needed to achieve simpler modification strategies that can still produce ultra-
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sensitive and clinically relevant detection of serum PCa-associated protein biomarkers. 
Increased availability of commercial multiplexed companion diagnostic devices could 
provide portable xPOCT devices in near-patient settings. For instance, bench-top analyz-
ers or handheld devices that do not require highly trained professionals could be used 
within a primary clinical setting, e.g., a hospital or a GP clinic. If the established handheld 
devices are patient-friendly, it could be beneficial for both primary healthcare profession-
als, but also for patients to use at home [140]. Thus, developing xPOCT devices that 
achieve sensitive and specific results using a minute serum sample, and are comparable to 
the results evaluated in clinical laboratories using conventional single-analyte protein de-
tection kits such as ELISA [20,141]. Moreover, efforts have been made to integrate wireless 
networks with xPOCT devices in order to effectively communicate and transfer real-time 
and highly sensitive results, aiding to prevent unnecessary misdiagnosis and unnecessary 
treatment [20,90,142]. Current research developments are focused on the detection of mul-
tiple proteins biomarkers in relation to early PCa screening and diagnosis. However, there 
is a greater need in the future for multiplexed PCa companion diagnostic devices to aid 
clinicians who need to make a conclusive decision on the ideal treatment pathway to be 
considered. Therefore, the provision of highly personalized approaches to PCa treatment 
management, particularly during key diagnostic, active surveillance or monitoring mile-
stones while PCa patients are undergoing treatment, is in great need [21,140]. 
Many different methods have been identified in this review that could lead to multi-
plexed systems, some with extremely low limits of detection and/or high selectivity. How-
ever, each system would have advantages and drawbacks, and which would make it to 
market depends mostly on the clinical application: test by healthcare professional versus 
test at home, clinical ranges required, diagnostic or monitoring, number of proteins re-
quired to be measured, sample volumes available, cost, etc. It should also be noted that 
although we focused on protein biomarkers, a range of other biomarkers are of interest 
for PCa diagnosis and, in particular PCa prognosis such as microRNAs, circulating tumor 
DNA (ctDNA), circulating tumor cells (CTCs), etc. Several of the systems described could 
integrate true multiplexing capabilities by measuring different types of biomarkers. 
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